Gold prices rebound after heavy losses; U.S.-China tensions resurface
Investing.com -- Ideaya Biosciences Inc (NASDAQ:IDYA) stock rose 4.9% in Monday premarket trading after the precision medicine oncology company presented positive clinical data from its Phase 2 OptimUM-09 trial of darovasertib in patients with primary uveal melanoma.
The data, presented at the European Society of Medical Oncology in Berlin, showed that darovasertib demonstrated meaningful tumor shrinkage and eye preservation in patients with the rare eye cancer. Among patients initially recommended for eye removal (enucleation), 57.1% were able to preserve their eyes after treatment. This figure jumped to 95% for patients who achieved at least 20% tumor shrinkage.
The trial included 95 primary uveal melanoma patients across two cohorts - 56 patients recommended for enucleation and 39 patients eligible for plaque brachytherapy. Approximately 84% of patients in the enucleation cohort and 82% in the brachytherapy cohort experienced tumor reduction.
The company also reported improvements in visual acuity, with 54.7% of patients in the enucleation cohort and 60.5% in the brachytherapy cohort showing better vision during treatment.
"We are highly encouraged by the data from OptimUM-09 demonstrating meaningful tumor shrinkage, eye preservation and reduced predicted risk of severe vision loss, and believe these results strongly support the potential for darovasertib as the first systemic therapy for the neoadjuvant treatment of primary uveal melanoma," said Darrin Beaupre, Chief Medical Officer of IDEAYA Biosciences.
The drug was generally well-tolerated with manageable side effects. Ideaya is currently conducting a Phase 3 trial of darovasertib in primary uveal melanoma and expects to report data from another trial in metastatic uveal melanoma by early 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.